REGN Maintained by JP Morgan -- Price Target Raised to $950

Genmab and AbbVie's Epkinly showed promising results in a Phase 3 study, reducing disease progression or death risk by 51% in lymphoma patients. IntraBio was acquired by Shionogi for $2 billion, expanding Aqneursa's approvals. Novartis invested up to $7.8 billion in Abogen Biosciences. Eli Lilly and CSL also announced significant biopharma deals. Sarepta Therapeutics presented positive Elevidys data, with upcoming catalysts for its treatments.

Regeneron (REGN) announced a $22M Q3 R&D charge, reducing EPS by $0.18. The company expanded its partnership with Sanofi (SNY) in an $8B deal, including a $1B upfront payment for immunology therapies. REGN's GF Value™ suggests it is modestly undervalued with a 19.7% margin of safety. The GF Score™ is 87/100, indicating strong fundamentals. Insider activity shows $12.9M in selling over the past year, while 10 premium gurus hold REGN shares, with 8 adding and 4 trimming positions.

Regeneron and Sanofi expanded their antibody collaboration, adding four new targets and settling a lawsuit. Sanofi will pay $1.0 billion upfront and up to $7.0 billion in milestones. Regeneron retains U.S. regulatory roles, while Sanofi leads commercialization. Analysts rate REGN stock a Buy with a $950 target.

Regeneron and Sanofi expanded their antibody collaboration, targeting four new antibodies. Sanofi will pay $1.0 billion upfront, with up to $7.0 billion in milestones. They will share profits and costs, with Regeneron leading U.S. efforts and Sanofi leading global commercialization. The agreement aims to expand their IL-4/IL-13 immunology pipeline.

REGENERON PHARMACEUTICALS, INC. (REGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 1.01. Entry into a Material Definitive Agreement. On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“ Regeneron ” or the “ Company ”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“ Sanofi Biotechnol

Regeneron (NASDAQ: REGN) presented new clinical data at ESMO 2026, including long-term survival outcomes for Libtayo in high-risk CSCC and neoadjuvant treatment data. The company also shared updates on Factor XI antibodies for cancer-associated thrombosis. Regeneron's pipeline includes over 30 cancer types, with Libtayo as a key therapy.